ACLX Michelle Gilson sells $791K worth of shares
Feb 19, 2026, 5:38 AM
0.00%
What does ACLX do
Arcellx, based in Redwood City, California, focuses on innovative immunotherapies for cancer, with its lead product, CART-ddBCMA, in pivotal Phase II trials for multiple myeloma. The company also develops two clinical-stage programs targeting BCMA and CD123 in various blood cancers.
Michelle Gilson sold 11,291 shares of ACLX on 17 February at $70.01 per share, worth a total of $791K. They now own 57,691 ACLX shares, or a 17% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.